KRAS-Mutant, Microsatellite-Stable Metastatic Colorectal Cancer

Disease

Also known as: KRAS-mutant, microsatellite-stable metastatic colorectal cancer

Related News

Global Oncology Market Projected to Reach $748 Billion by 2035 on Immunotherapy Growth

Mar 03, 2026

The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.

Oncolytics Biotech Gains FDA Fast Track for Pelareorep in KRAS-Mutant Colorectal Cancer

Feb 15, 2026

Oncolytics Biotech announced FDA Fast Track Designation for pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant metastatic colorectal cancer, driving shares up 19.7%.